© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 24, 2022
Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.
September 23, 2022
The combination of toripalimab and chemotherapy displayed promising efficacy results in a phase 2 study.
August 25, 2022
Certain patients with Wilm's tumor-expressing solid tumors are eligible to be treated with an investigational agent in a phase 1 clinical trial.
August 18, 2022
In the PIONEER study, clinically meaningful benefit was shown with avapritinib in patients with non-advanced systemic mastocytosis across both primary and secondary end points.
August 17, 2022
Sanofi has discontinued the clinical development program for amcenestrant due to unsatisfactory results from the phase 3AMEERA-5 trial.